JPM
JPMorgan Chase & Co.
JPM has lower modeled downside risk, despite its lower overall score.
PACS
PACS Group, Inc.
PACS has the edge over JPM overall, supported by stronger valuation and stronger fundamentals.
JPM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
JPM's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like JPM.
PACS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| N/A | |
| N/A |
PACS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like PACS.
JPM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.7x | $231 | -33% |
| Fair | 12x | $287 | -16% |
| Current | 14x | $343 | — |
| Forward | 14x | $343 | — |
| Expensive | 15x | $361 | +5.2% |
Historical ranges are pointers, not guarantees.
JPM has the edge over PACS in the historical PE scenario, which offers more potential upside but is not a forecast.
PACS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 17x | $30.55 | -36% |
| Forward | 18x | $48.00 | — |
| Fair | 24x | $43.08 | -10% |
| Current | 27x | $48.00 | — |
| Expensive | 34x | $60.12 | +25% |
Historical ranges are pointers, not guarantees.
PACS's PE is in its fair range at 27x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
JPM Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for JPM, with profitability improving.
PACS Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Limited | |
| Moderate |
PACS has the edge over JPM on the outlook, with more favorable valuation expectations.
JPM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $24.99 | +4.8% |
| Q3 2026 | $23.85 | +18% |
| Q2 2026 | $23.35 | +20% |
| Q1 2026 | $20.89 | +2.5% |
| Q4 2025 | $20.02 | +1.4% |
| Q3 2025 | $20.20 | +12% |
| Q2 2025 | $19.50 | +8.7% |
| Q1 2025 | $20.38 | +23% |
| Q4 2024 | $19.75 | +22% |
JPM's earnings per share have climbed steadily: $23.85 over the past year, up 18% from the year before, and higher year over year for 15 quarters in a row.
PACS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.64 | +50% |
| Q3 2026 | $1.76 | +73% |
| Q2 2026 | $1.71 | +114% |
| Q1 2026 | $1.55 | +269% |
| Q4 2025 | $1.22 | +94% |
| Q3 2025 | $1.02 | +59% |
| Q2 2025 | $0.80 | +19% |
| Q1 2025 | $0.42 | -52% |
| Q4 2024 | $0.63 | -16% |
PACS earned $1.76 per share over the past year, up 73% from the year before.
JPM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $50.2B | +8.1% |
| Q2 2026 | $57.3B | +28% |
| Q1 2026 | $49.8B | +10% |
| Q4 2025 | $45.8B | +7.1% |
| Q3 2025 | $46.4B | +8.8% |
| Q2 2025 | $44.9B | -11% |
| Q1 2025 | $45.3B | +8.1% |
| Q4 2024 | $42.8B | +11% |
JPM's revenue has grown year over year for five quarters in a row: $50.2B last quarter, up 8.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 40% | -0.2 points |
| Q2 2026 | 48% | +7.3 points |
| Q1 2026 | 41% | +0.5 points |
| Q4 2025 | 37% | -3.2 points |
| Q3 2025 | 40% | +0.6 points |
| Q2 2025 | 41% | -6 points |
| Q1 2025 | 41% | -0.6 points |
| Q4 2024 | 41% | +11 points |
JPM has the edge over PACS on profitability, with a higher operating margin.
PACS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.5B | +11% |
| Q2 2026 | $1.4B | +9.1% |
| Q1 2026 | $1.4B | +11% |
| Q4 2025 | $1.4B | +12% |
| Q3 2025 | $1.3B | +31% |
| Q2 2025 | $1.3B | +33% |
| Q1 2025 | $1.3B | +37% |
| Q4 2024 | $1.2B | +42% |
PACS has the edge over JPM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.7% | +0.2 points |
| Q2 2026 | 7.7% | +1.5 points |
| Q1 2026 | 8.4% | +4.7 points |
| Q4 2025 | 7% | +1 points |
| Q3 2025 | 6.4% | +4.2 points |
| Q2 2025 | 6.2% | +6.1 points |
| Q1 2025 | 3.8% | -4.8 points |
| Q4 2024 | 6% | -6 points |
PACS's operating margin was 6.7% last quarter, about level with the same quarter a year ago.
JPM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $33.2B | +$78.4B |
| Q2 2026 | -$25.3B | -186% |
| Q1 2026 | -$211.8B | +$40.1B |
| Q4 2025 | $119.7B | -19% |
| Q3 2025 | -$45.2B | +$28.9B |
| Q2 2025 | $29.5B | -23% |
| Q1 2025 | -$251.8B | -$97.7B |
| Q4 2024 | $147.8B | +145% |
JPM's free cash flow was −$84.2B over the past year, against −$120B the year before. Free cash flow isn't a meaningful measure for financial services companies like JPM.
PACS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $178.7M | -4.3% |
| Q2 2026 | $109M | +221% |
| Q1 2026 | $214.5M | +62% |
| Q4 2025 | -$54.5M | -236% |
| Q3 2025 | $186.8M | -3.4% |
| Q2 2025 | $34M | +75% |
| Q1 2025 | $132.5M | +176% |
| Q4 2024 | $40M | +$64.9M |
PACS has the edge over JPM on cash generation, producing positive trailing cash flow while its opponent burns cash.
JPM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -11.2M shares |
| 1 year | -3.1% | -84.6M shares |
| 3 years | -8.5% | -249M shares |
| 5 years | -11% | -322M shares |
| Available history | -17% | -547M shares |
JPM has the edge over PACS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.1B |
| Q2 2026 | $6.8B |
| Q1 2026 | $8.3B |
| Q4 2025 | $8.3B |
| Q3 2025 | $8.3B |
| Q2 2025 | $7.5B |
| Q1 2025 | $7.5B |
| Q4 2024 | $4.3B |
JPM spent $24.5B buying back its own shares over the past year, down 11% from the year before.
PACS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +1.9M shares |
| 1 year | -0.5% | -794K shares |
| 3 years | +7.6% | +11.5M shares |
PACS has 164M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
JPM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.5x | Very low |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.4x | Very low |
JPM's net debt is less than a year of its operating earnings (EBITDA). Net leverage isn't a meaningful measure for financial services companies like JPM.
PACS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2024 | 0.9x | Very low |
| Q2 2024 | 0.7x | Very low |
| Q1 2024 | 0.6x | Very low |
| Q4 2023 | 10.2x | High |
PACS's net debt is less than a year of its operating earnings (EBITDA). Net leverage isn't a meaningful measure for financial services companies like PACS.
JPM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.8 | Neutral |
| Stochastic | 31.5 | Neutral |
JPM's weekly RSI is 55 (neutral) and its Stochastic is 31 (neutral).
PACS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 62.3 | Neutral |
| Stochastic | 75.8 | Neutral |
PACS's weekly RSI is 62 (neutral) and its Stochastic is 76 (neutral).
JPM PE vs Financial Services Sector
| Metric | JPM | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 13x | 10% above |
| PE % | 76 | 63 | 13 pts above |
JPM has the edge over PACS on valuation relative to its sector.
PACS PE vs Financial Services Sector
| Metric | PACS | Sector median | Relative |
|---|---|---|---|
| PE | 27x | 13x | 109% above |
| PE % | 63 | 30 | 33 pts above |
PACS is trading at 27x earnings, a 109% premium to the Financial Services sector's median of 13x.
JPM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $336.8 | 1.8% above |
| 20 week MA | $345.3 | 0.7% below |
| 50 week MA | $323.2 | 6.1% above |
| 100 week MA | $298.9 | 15% above |
| 200 week MA | $236.6 | 45% above |
PACS has stronger trend alignment. JPM is above 4 of 5 weekly averages versus PACS above 4 of 4.
PACS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $45.9 | 4.5% above |
| 20 week MA | $45.2 | 6.3% above |
| 50 week MA | $39.7 | 21% above |
| 100 week MA | $26.2 | 84% above |
PACS is in an uptrend: it's above all four of its weekly moving averages, and 84% above its 100-week average.
JPM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $139.1 | $124.5 | -11% |
| 2021 | $124.5 | $157.3 | +26% |
| 2022 | $157.3 | $131.3 | -17% |
| 2023 | $131.3 | $170.1 | +30% |
| 2024 | $170.1 | $241.2 | +42% |
| 2025 | $241.2 | $327.9 | +36% |
| 2026 YTD | $327.9 | $342.8 | +4.5% |
JPM has finished higher in four of the last six years. It's up 4.5% so far in 2026.
PACS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $24.0 | $13.0 | -46% |
| 2025 | $13.0 | $38.1 | +193% |
| 2026 YTD | $38.1 | $48.0 | +26% |
PACS has the edge over JPM on returns for 2026, with the stronger performance.